A groundbreaking medlinkAI/medlink technology could revolutionize breast cancer prevention and treatment. By identifying and analyzing damaged...

Using mammograms to detect heart disease: A new approach helping doctors spot early signs of cardiovascular risk through breast tissue imaging.

The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

A recent study from Flinders University in Australia has made a significant discovery that could change the way we understand cancer. This research...

Macquarie University researchers have discovered new information about how oral cancer cells may block the body's immune response. This could lead to...

MA strengthens its fraud prevention tools with AI enhancements, helping banks detect scams in real-time and driving revenue growth through innovative...

10 common breast cancer signs that you should never ignore.

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in...

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer,...